MC
TXMD icon

Moors & Cabot’s TherapeuticsMD TXMD Stock Holding History

Moors & Cabot’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-610
Closed -$12K – 917
2022
Q1 		$12K Hold
610
– – ﹤0.01% 857
2021
Q4 		$11K Sell
610
-40
-6% -$1.2K ﹤0.01% 856
2021
Q3 		$24K Sell
650
-79
-11% -$3.51K ﹤0.01% 827
2021
Q2 		$43K Buy
729
+23
+3% +$1.39K ﹤0.01% 795
2021
Q1 		$47K Buy
706
+16
+2% +$1.25K ﹤0.01% 744
2020
Q4 		$41K Sell
690
-376
-35% -$25.7K ﹤0.01% 713
2020
Q3 		$84K Hold
1,066
– – 0.01% 662
2020
Q2 		$67K Buy
1,066
+16
+2% +$932 0.01% 634
2020
Q1 		$55K Sell
1,050
-16
-2% -$1.59K 0.01% 564
2019
Q4 		$128K Buy
1,066
+232
+28% +$33.4K 0.01% 590
2019
Q3 		$152K Buy
834
+634
+317% +$89.4K 0.02% 569
2019
Q2 		$25K Buy
+200
New +$35.9K ﹤0.01% 542

Other funds holding TXMD

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

Moors & Cabot's TXMD Position: Q2 2022 in Review

Moors & Cabot sold out of TherapeuticsMD (TXMD) in Q2 2022, closing a stake of 610 shares — an estimated $12K sold.

Moors & Cabot first reported a position in TXMD in Q2 2019 and held it in 12 quarters. The position peaked at $152K in Q3 2019. 53 funds tracked by Wall St. Rank hold TXMD as of Q2 2022.

  • Moors & Cabot reported no remaining TherapeuticsMD position as of Q2 2022 after selling out during the quarter.
  • Moors & Cabot sold 610 TherapeuticsMD shares in Q2 2022, an estimated $12K.
  • Moors & Cabot first reported a position in TherapeuticsMD in Q2 2019 and held it in 12 quarters.
  • Moors & Cabot's TherapeuticsMD position peaked at $152K in Q3 2019.
  • 53 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2022.

Based on Moors & Cabot's 13F filing for Q2 2022, filed 8 Aug 2022.